Search
Metastatic Breast Cancer Clinical Trials
A listing of 64 Metastatic Breast Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
61 - 64 of 64
There are currently 64 active clinical trials seeking participants for Metastatic Breast Cancer research studies. The states with the highest number of trials for Autism participants are Texas, California, Florida and New York.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Hyperacusis Activities Treatment-Online Study
Recruiting
Are you experiencing hyperacusis? If so, we are recruiting adults with hyperacusis to complete a clinical trial supported by the National Institutes of Health. The study involves participating in a remote counseling program and sound therapy trial for hyperacusis, Hyperacusis Activities Treatment-Online.
Conditions:
Hyperacusis
Tinnitus
Hearing Loss
Her2-BATS and Pembrolizumab in Metastatic Breast Cancer
Recruiting
This proposal uses HER2Bi armed activated T-cells (HER2 BATs) to target breast cancer in combination with pembrolizumab (PBZ) in women with metastatic breast cancer (MBC). Phase I will determine a safe dose of the combination of PBZ and HER2 BATs in 3 to 18 patients. In the phase II portion, an additional 12 patients will be treated at the selected dose to further evaluate the safety and preliminary efficacy.
Study treatment includes a combination of 8 infusions of BATs using a previously estab... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/18/2023
Locations: Ashley Donihee, Charlottesville, Virginia
Conditions: Metastatic Breast Cancer
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)
Recruiting
For patients with ER-positive, HER2-negative breast cancer, blockage of the ER pathway has been proven to be an effective anticancer approach. These patients showed good response to endocrine therapy.
Fulvestrant, the approved SERD as monotherapy or in combination with CDK4/6 inhibitors, showed superior clinical benefit compared to other endocrine therapies. Fulvestrant exhibits differential mechanism of action from other endocrine therapy, such as tamoxifen, aromatase inhibitors, which indicat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2022
Locations: Swedish Cancer Institute, Seattle, Washington +7 locations
Conditions: Estrogen Receptor-Positive, HER2-Negative, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
Recruiting
This is a phase 2, open-label, single-arm trial designed to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) in combination with pembrolizumab following disease progression after two prior lines of standard therapy in unresectable metastatic stage IV breast cancer
Gender:
Female
Ages:
18 years and above
Trial Updated:
11/05/2021
Locations: James Graham Brown Cancer Center, Louisville, Kentucky
Conditions: Metastatic Breast Cancer
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
Recruiting
This will be a single arm, open label pilot to test the combination of dapagliflozin, a commercially available SGLT-2 inhibitor, in combination with alpelisib + fulvestrant in patients with HR+/HER2- mBC. The objective of this study is to determine if the addition of dapagliflozin to the combination of alpelisib and fulvestrant leads to significant reduction in all-grade hyperglycemia.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
10/14/2021
Locations: Saint Luke's Cancer Institute, Kansas City, Missouri
Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer
61 - 64 of 64